Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting in Patients With Inadequate Response to One or Several Conventional DMARDs Including Methotrexate in France. A Database Analysis Based on the ACTION Study

Trial Profile

Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting in Patients With Inadequate Response to One or Several Conventional DMARDs Including Methotrexate in France. A Database Analysis Based on the ACTION Study

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ReACTION
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 03 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Jan 2018, according to ClinicalTrials.gov record.
    • 03 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2018, according to ClinicalTrials.gov record.
    • 03 Feb 2016 Planned initiation date changed to 1 Sep 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top